Cargando…

Current status of cardiac regenerative medicine; An update on point of view to cell therapy application

Cardiovascular diseases (CVDs) are the leading cause of death globally. Because of the economic and social burden of acute myocardial infarction and its chronic consequences in surviving patients, understanding the pathophysiology of myocardial infarction injury is a major priority for cardiovascula...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassanpour, Mehdi, Aghamohamadzade, Nasser, Cheraghi, Omid, Heidarzadeh, Morteza, Nouri, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828760/
https://www.ncbi.nlm.nih.gov/pubmed/33510874
http://dx.doi.org/10.34172/jcvtr.2020.44
_version_ 1783641084406005760
author Hassanpour, Mehdi
Aghamohamadzade, Nasser
Cheraghi, Omid
Heidarzadeh, Morteza
Nouri, Mohammad
author_facet Hassanpour, Mehdi
Aghamohamadzade, Nasser
Cheraghi, Omid
Heidarzadeh, Morteza
Nouri, Mohammad
author_sort Hassanpour, Mehdi
collection PubMed
description Cardiovascular diseases (CVDs) are the leading cause of death globally. Because of the economic and social burden of acute myocardial infarction and its chronic consequences in surviving patients, understanding the pathophysiology of myocardial infarction injury is a major priority for cardiovascular research. MI is defined as cardiomyocytes death caused by an ischemic that resulted from the apoptosis, necrosis, necroptosis, and autophagy. The phases of normal repair following MI including inflammatory, proliferation, and maturation. Normal repair is slow and inefficient generally so that other treatments are required. Because of difficulties, outcomes, and backwashes of traditional therapies including coronary artery bypass grafting, balloon angioplasty, heart transplantation, and artificial heart operations, the novel strategy in the treatment of MI, cell therapy, was newly emerged. In cell therapy, a new population of cells has created that substitute with damaged cells. Different types of stem cell and progenitor cells have been shown to improve cardiac function through various mechanisms, including the formation of new myocytes, endothelial cells, and vascular smooth muscle cells. Bone marrow- and/or adipose tissue-derived mesenchymal stem cells, embryonic stem cells, autologous skeletal myoblasts, induced pluripotent stem cells, endothelial progenitor cells, cardiac progenitor cells and cardiac pericytes considered as a source for cell therapy. In this study, we focused on the point of view of the cell sources.
format Online
Article
Text
id pubmed-7828760
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Tabriz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-78287602021-01-27 Current status of cardiac regenerative medicine; An update on point of view to cell therapy application Hassanpour, Mehdi Aghamohamadzade, Nasser Cheraghi, Omid Heidarzadeh, Morteza Nouri, Mohammad J Cardiovasc Thorac Res Review Article Cardiovascular diseases (CVDs) are the leading cause of death globally. Because of the economic and social burden of acute myocardial infarction and its chronic consequences in surviving patients, understanding the pathophysiology of myocardial infarction injury is a major priority for cardiovascular research. MI is defined as cardiomyocytes death caused by an ischemic that resulted from the apoptosis, necrosis, necroptosis, and autophagy. The phases of normal repair following MI including inflammatory, proliferation, and maturation. Normal repair is slow and inefficient generally so that other treatments are required. Because of difficulties, outcomes, and backwashes of traditional therapies including coronary artery bypass grafting, balloon angioplasty, heart transplantation, and artificial heart operations, the novel strategy in the treatment of MI, cell therapy, was newly emerged. In cell therapy, a new population of cells has created that substitute with damaged cells. Different types of stem cell and progenitor cells have been shown to improve cardiac function through various mechanisms, including the formation of new myocytes, endothelial cells, and vascular smooth muscle cells. Bone marrow- and/or adipose tissue-derived mesenchymal stem cells, embryonic stem cells, autologous skeletal myoblasts, induced pluripotent stem cells, endothelial progenitor cells, cardiac progenitor cells and cardiac pericytes considered as a source for cell therapy. In this study, we focused on the point of view of the cell sources. Tabriz University of Medical Sciences 2020 2020-11-24 /pmc/articles/PMC7828760/ /pubmed/33510874 http://dx.doi.org/10.34172/jcvtr.2020.44 Text en © 2020 The Author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Hassanpour, Mehdi
Aghamohamadzade, Nasser
Cheraghi, Omid
Heidarzadeh, Morteza
Nouri, Mohammad
Current status of cardiac regenerative medicine; An update on point of view to cell therapy application
title Current status of cardiac regenerative medicine; An update on point of view to cell therapy application
title_full Current status of cardiac regenerative medicine; An update on point of view to cell therapy application
title_fullStr Current status of cardiac regenerative medicine; An update on point of view to cell therapy application
title_full_unstemmed Current status of cardiac regenerative medicine; An update on point of view to cell therapy application
title_short Current status of cardiac regenerative medicine; An update on point of view to cell therapy application
title_sort current status of cardiac regenerative medicine; an update on point of view to cell therapy application
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828760/
https://www.ncbi.nlm.nih.gov/pubmed/33510874
http://dx.doi.org/10.34172/jcvtr.2020.44
work_keys_str_mv AT hassanpourmehdi currentstatusofcardiacregenerativemedicineanupdateonpointofviewtocelltherapyapplication
AT aghamohamadzadenasser currentstatusofcardiacregenerativemedicineanupdateonpointofviewtocelltherapyapplication
AT cheraghiomid currentstatusofcardiacregenerativemedicineanupdateonpointofviewtocelltherapyapplication
AT heidarzadehmorteza currentstatusofcardiacregenerativemedicineanupdateonpointofviewtocelltherapyapplication
AT nourimohammad currentstatusofcardiacregenerativemedicineanupdateonpointofviewtocelltherapyapplication